| pubmed-article:14640057 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14640057 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:14640057 | lifeskim:mentions | umls-concept:C0009402 | lld:lifeskim |
| pubmed-article:14640057 | lifeskim:mentions | umls-concept:C0033551 | lld:lifeskim |
| pubmed-article:14640057 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:14640057 | pubmed:issue | 45 | lld:pubmed |
| pubmed-article:14640057 | pubmed:dateCreated | 2003-11-26 | lld:pubmed |
| pubmed-article:14640057 | pubmed:abstractText | Epidemiological studies have found that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a lower risk of colorectal cancer (CRC). Cyclooxygenase (COX)-2 expression is present in colorectal cancer and overexpression is associated with metastases and poorer prognosis in multivariate analysis. NSAID treatment results in a reduction of the incidence of colorectal adenoma in patients with familial adenomatous polyposis, in patients with a history of colorectal adenomas and in patients with a history of CRC. Pre-clinical research shows that COX-2 expression is associated with cell proliferation, angiogenesis, apoptosis inhibition and local immune-down modulation. An anticarcinogenic effect has been shown specifically in selective COX-2 inhibitors in animal models. Selective COX-2 inhibitors have fewer adverse effects than the non-selective NSAIDs and are promising chemopreventative and chemotherapeutical agents. The effects of selective COX-2 inhibition in the prevention of and treatment for colorectal carcinoma will be investigated in clinical randomized multicentre trials. | lld:pubmed |
| pubmed-article:14640057 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14640057 | pubmed:language | dut | lld:pubmed |
| pubmed-article:14640057 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14640057 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14640057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14640057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14640057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14640057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14640057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14640057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14640057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14640057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14640057 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14640057 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:14640057 | pubmed:issn | 0028-2162 | lld:pubmed |
| pubmed-article:14640057 | pubmed:author | pubmed-author:RichelD JDJ | lld:pubmed |
| pubmed-article:14640057 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:14640057 | pubmed:author | pubmed-author:HulscherJ BJB | lld:pubmed |
| pubmed-article:14640057 | pubmed:author | pubmed-author:StellerE PhEP | lld:pubmed |
| pubmed-article:14640057 | pubmed:author | pubmed-author:TuynmanJ BJB | lld:pubmed |
| pubmed-article:14640057 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14640057 | pubmed:day | 8 | lld:pubmed |
| pubmed-article:14640057 | pubmed:volume | 147 | lld:pubmed |
| pubmed-article:14640057 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14640057 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14640057 | pubmed:pagination | 2207-12 | lld:pubmed |
| pubmed-article:14640057 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:meshHeading | pubmed-meshheading:14640057... | lld:pubmed |
| pubmed-article:14640057 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14640057 | pubmed:articleTitle | [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma]. | lld:pubmed |
| pubmed-article:14640057 | pubmed:affiliation | Sint Lucas Andreas Ziekenhuis, locatie Lucas, afd. Heelkunde, Amsterdam. j.b.tuynman@amc.uva.nl | lld:pubmed |
| pubmed-article:14640057 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14640057 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:14640057 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14640057 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14640057 | lld:pubmed |
